For consideration of Rs 75 crore
Pfizer has entered into an Acquisition Agreement with AstraZeneca AB, Sweden ('AstraZeneca'), pursuant to which the brand 'Neksium' is being acquired by the Company in India for a consideration of Rs. 75 crore, subject to completion of necessary conditions precedent.Neksium (esomeprazole) complements the Company's existing product portfolio in the gastrointestinal (GI) therapeutic area.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content